Introduction
============

Type 1 diabetes mellitus (DM1) is characterized by the destruction of insulin-producing β-cells in the pancreas, with consequent insulin deficiency.[@b1-dmso-11-289] It is a metabolic and endocrine condition more common in childhood development and is preceded by the dysregulation of many biological pathways.[@b2-dmso-11-289] At present, no therapy exists to halt the immune-mediated destruction of β-cells,[@b3-dmso-11-289] and DM1 has a substantial long-term impact on the quality of life, particularly in children and adolescents.

According to the International Diabetes Federation,[@b4-dmso-11-289] the total population with DM was equivalent to 415 million and is estimated to increase to 471 million by 2035. A recent report of World Health Organization estimated that, globally, 422 million adults aged \>18 years were living with diabetes in 2014, compared with 108 million in 1980.[@b5-dmso-11-289] Following the same trend, the incidence of DM1 has increased bŷ3% worldwide and represents 5%--10% of the entire population with diabetes.[@b6-dmso-11-289]

There has been a lot of research conducted on diabetes over the decades. Several proteomic approaches have been undertaken to identify biomarkers for monitoring the prediction[@b7-dmso-11-289],[@b8-dmso-11-289] and progression[@b9-dmso-11-289] of the disease. However, there are some limitations due to low specificity or late application to the disease stage.[@b10-dmso-11-289]

DM1 is a complex disease with altered expression of many genes and their products.[@b11-dmso-11-289] Therefore, different approaches were developed using current proteomic technologies to explore its clinical potential and enable the discovery of new biomarkers for DM1.

Recent advances in proteomics have triggered rapid progress in mass spectrometry (MS)-based proteomics. It enables more than simple protein identification and can accurately and reliably quantitate differences in protein abundance in an organism, a cell, or a tissue at a given time or under a particular condition.[@b12-dmso-11-289] The label-free technique has been shown to be more accurate in estimating absolute abundance of proteins in complex samples.[@b13-dmso-11-289]

In the current study, we performed a quantitative and qualitative analysis using a sample pretreatment immunodepletion of serum albumin and immunogloblin G (IgG) combined with data-independent label-free mass spectrometry (MS^E^) analysis with the aim of identifying differentially expressed levels of serum proteins in DM1 patients and healthy controls (HCs).

Materials and methods
=====================

Study participants
------------------

The present study enrolled DM1 patients selected among those in a regular follow-up in the outpatient of Endocrinology and Diabetes at the Federal University Hospital of Ceara, Fortaleza, Brazil. DM1 patients aged ≥18 years, both male and female, who had attended the outpatient department of Endocrinology and Diabetes for a minimum of 6 months, with clinical and cognitive conditions to answer an interview and the capacity to stand up normally were eligible for the DM1 group. Patients using immunosuppressive medications (renal, heart, or hepatic dysfunction; type 2 diabetes; etc.); those with alcoholism and mental disorders (including dementia and Alzheimer's disease); those diagnosed with leprosy or HIV infection; and those with autoimmune disease, amputation or ulcers on the lower limbs, acute infectious frames, or diabetic ketoacidosis in the 3 months preceding the evaluation, as well as pregnant or lactating females, were excluded. HCs were selected from the Federal University and Ceará State University, considering the same criteria used for DM1 patients, besides not having a familiar history of diabetes and with fasting blood glucose ≤99 mg/dL.

The study initially enrolled all patients attending the outpatient department as potential participants. After applying rigorous inclusion and exclusion criteria to achieve a group with highly homogeneous clinical features and accounting for loss during the selection process, a total of 60 subjects were included as study participants: 30 DM1 patients and 30 HCs. The DM1 and HC groups were matched by gender, age, body mass index (BMI), total cholesterol, high-density lipoprotein cholesterol (HDL-C), serum low-density lipoprotein cholesterol (LDL-C), total protein, urea, and creatinine. General health features, demographics, and clinical data were obtained through medical records and direct interviews. The study protocol (number 1357544) was approved by the Federal University Hospital of Ceará Ethics Committee, and the study was conducted according to the principles of the Declaration of Helsinki. Written informed consent was obtained from all the participants.

Anthropometry and health-related behaviors
------------------------------------------

Weight and height were measured according to the SISVAN (Food and Nutritional Surveillance System; 2004).[@b14-dmso-11-289] BMI was calculated as weight (in kg) divided by height (in m^2^).[@b15-dmso-11-289] The considered standard doses for alcohol consumption and categories were in accordance with World Health Organization.[@b16-dmso-11-289] Cigarette smoking status was consistent with that shown in Vital and Health Statistics.[@b17-dmso-11-289]

Serum samples
-------------

Blood samples were collected from all subjects after an overnight fast (12 hours) for biochemical analysis. All the samples were centrifuged at 3000 rpm for 15 minutes at room temperature, and the serum obtained was kept frozen at −80°C until analyzed. Fasting blood sugar, total cholesterol, HDL-C, triglyceride, urea, and creatinine were measured by colorimetric enzymatic method using commercially available kits (Bioclin, Quibasa Quimica Basica Ltda, Belo Horizonte, Minas Gerais, Brazil) and an automated biochemical analyzer (Mindray BC-2800; Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Shenzhen, China). LDL-C was calculated using the Frederickson--Friedewald equation.[@b18-dmso-11-289] C-peptide analysis was performed by immunoassays of microparticles by quimioluminescence (Kit ARCHITECT C-Peptide) using Architec Asystema no. i2000 (Chicago, IL, USA). Samples were analyzed in triplicate.

The serum protein concentration was determined by the Bradford method.[@b19-dmso-11-289] The serum samples were pooled in the same group for proteomic analysis. Using 5.33 μg of protein from each individual sample, 15 samples were pooled to form each group of patients with diabetes and the HC groups. Therefore, two pools of samples from patients with DM1 (DM1a and DM1b) and two pools of HCs (HCa and HCb) were generated.

Immunodepletion of high-abundance proteins
------------------------------------------

In order to improve the chance of detecting a wide range of serum proteins of medium to low abundance, proteins of high abundance, albumins, and immunoglobulins were depleted from the serum. Aliquots of serum were filtered through 0.22-μM membrane (KASVI, São José do Pinhais, Brazil). Then, 150 μL of filtered serum was applied to a HiTrap® Albumin & IgG Depletion column (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) attached to an AKTA Purifier 10 fast protein liquid chromatography system (GE Healthcare). The column was preequilibrated with a solution of 20 mM Tris--HCl (pH 7.4) and 0.15 M NaCl. The elution of fraction rich in albumin and immunoglobulin was realized with 0.1 M Glycine--HCL buffer (pH 2.7) delivered at 1 mL/min, and absorbance was monitored at 216 and 280 nm.

Nano-ultra performance liquid chromatografy MS analysis
-------------------------------------------------------

After immunodepletion, the fractions of the pools were dia-lyzed, concentrated, and quantified using a Vivaspin™ (GE Healthcare) and a NanoVue™ Spectrometer (GE Healthcare), respectively, at an absorbance at 280 nm. The denatured samples (100 μg) were diluted in 50 mM ammonium bicarbonate, denatured with a solution of 0.2% RapiGest™ SF (Waters Corporation, Milford, MA, USA) at 80°C for 15 minutes in a dry bath, and reduced with 100 mM dithiothreitol at 60°C for 60 minutes, and alkylation with 300 mM iodoacetamide for 30 minutes was performed in the dark at room temperature. The digestion occurred with the addition of 1 μg of modified trypsin (Promega, Madison, WI, USA) to each sample at 37°C, and the samples were incubated overnight. The reaction was stopped by adding 10 μL of 5% of trifluoroacetic acid, the samples were incubated for 90 minutes at 37°C, centrifuged, and the supernatant was transferred to vial (Waters, Manchester, UK). Tryptic peptides of yeast alcohol dehydrogenase (ADH) were added to vials containing digested proteins to a final concentration of 50 fmol/μL as internal standards. The final protein concentration was \~1 μg/μL.

The tryptic peptides were separated using a nanoAC-QUITY UPLC® system (Waters) equipped with an HSS T3 C18 reverse-phase column (1.8 μm, 75 μm×20 mm; Waters) for 110 minutes using 0%--40% gradient for 90 minutes and 40%--85% for 5 minutes. The column was reequilibrated for 15 minutes at 35°C. The flow rate was 0.35 μL/min, and mobile Phases A and B contained 0.1% formic acid in water and 0.1% formic acid in acetonitrile, respectively. All the samples were measured in triplicate. MS^E^ was performed using a Synapt HDMS (nano-electrospray ionization quadrupole/orthogonal acceleration time-of-flight mass spectrometer; Waters, Manchester, UK). The equipment was operated in "V" mode with a precursor double-charge resolution ≥10,000 full width at half maximum and in electrospray positive-ion mode nano-electrospray ionization (+). Mass spectrometer data were acquired using a NanoLockSpray probe channel infusion of Glu-fibrinogen peptide (Glu-Fib) derived from fibrinopeptide B human (M + 2H)[@b2-dmso-11-289] and final calibration of the equipment used MS/MS Glu-Fib fragments.

Data processing and protein identification and quantification
-------------------------------------------------------------

Liquid chromatography (LC)/MS^E^ data were processed, and the proteins were identified using the ProteinLynx Global Server (PLGS) version 2 software with the UniProt reverse Homo sapiens annotated database. For searching spectra and the database, the default parameters of PLGS were used, followed by a maximum of one missed trypsin cleavage. The absolute quantification of each run was calculated according to the three most intense peptides (label-free Hi3 method) using ADH peptides as internal standards.[@b13-dmso-11-289] Relative quantification of identified proteins from each expression group was performed using alpha-1-antitrypsin (UniProt) as an internal common housekeeping protein to normalize expression levels, using PLGS Expression^E^ software (Waters).[@b20-dmso-11-289] The average quantitative values of all the samples were calculated, and the *p*-values (\<0.05) were calculated using Expression^E^ software to refer to the differences between biological replicates.

Gene ontology analysis
----------------------

The identified proteins were classified into different categories, as biological processes, cellular location, and molecular function in accordance with the information found in the Gene Ontology database, UniProtKB, and EBI GOA.

Statistical analysis
--------------------

The data obtained concerning demographics and biochemical and anthropometric parameters were analyzed using R software Version 3.2.2 (2017). For the comparison of two means, Student's *t*-test was used for independent samples; otherwise, Mann--Whitney *U* test was used. Correlations between variables were tested using Pearson and Spearman correlation tests. Data were considered significant with *p*-values \<0.05. [Figure 1](#f1-dmso-11-289){ref-type="fig"} presents the experimental strategy used in this study.

Results
=======

Clinical features
-----------------

A total of 60 individuals with an average age of 33.30±9.80 years (ranging from 18 to 59 years) were studied and grouped into 30 DM1 patients and 30 HC individuals. [Table 1](#t1-dmso-11-289){ref-type="table"} shows the biochemical and anthropometric characteristics of the patients enrolled for the study. DM1 and HC groups were matched, and there were no significant differences between the groups regarding age, gender, and BMI or in the serum concentrations of total cholesterol, HDL-C, LDL-C, total proteins, and creatinine. As expected, fasting blood glucose and C-peptide were significantly different between DM1 patients and HCs (*p*\<0.001). The DM1 group also exhibited a negative correlation between C-peptide and duration of disease (*r*=−532; *p*\<0.001). Moreover, no significant differences were observed between the groups relative to alcohol consumption and cigarette smoking status.

Expression of proteins
----------------------

A comparative proteomic analysis was performed between DM1 and HC groups to investigate alterations in serum proteins in DM1 patients. In the current study, a total of 130 proteins were identified in the serum of the DM1 and HC groups in the total data set ([Table S1](#SD1-dmso-11-289){ref-type="supplementary-material"}). Eight proteins were differentially expressed in the serum of the DM1 group compared with the HC group (six proteins were upregulated and two were downregulated). Of the list of proteins identified, the criteria stated for the differential expression in each of the two biological replicates only considered proteins with differential expression (DM1/HC) with absolute ratios \>1.5 (upregulated) and \<0.66 (downregulated) and the levels of those proteins with ratios between 1.5 and 0.66 (unchanged). Based on gene ontology analysis, most of the proteins that were identified as related to molecular function were involved in binding (48%), catalytic (12.35%) and antioxidant (4.16%) activities, and other functions. They also participated in biological processes related to regulation (19.81%), cellular process (19.81%), localization (14.12%), stimulus response (9.58%), and immune system (9.75%), among others. In addition, the majority of proteins were located in the extracellular region ([Figure 2](#f2-dmso-11-289){ref-type="fig"}). [Table 2](#t2-dmso-11-289){ref-type="table"} shows the proteins identified as differentially expressed in the serum from DM1 group compared with HC group.

Discussion
==========

Diabetes occurs as a result of a range of minor changes in protein expression that alters the stability of the health β-cell to a prediabetic phenotype of instability and possibly β-cell destruction.[@b21-dmso-11-289] Thus, the proteomic analysis of protein expression is an important tool for understanding the molecular modifications associated with disease progression and may contribute to the therapeutic monitoring of this autoimmune disease.

In the present study, a proteomic approach using a label-free quantitative MS analysis identified eight differentially expressed proteins in the serum of DM1 patients compared with HCs. All the proteins that were either upregulated (alpha-2-macroglobulin \[α2M\], apolipoprotein A-II \[ApoA-II\], β2 glycoprotein I, Ig alpha-2 chain C region \[IGHA2\], alpha-1-microglobulin \[AMBP\], and prothrombin \[THRB\]) or downregulated (pregnancy zone protein \[PZP\] and complement C4 \[C4\]) are discussed below.

α2M belongs to the α-M family of proteins and is the largest major antiproteinase present in the plasma of vertebrates.[@b22-dmso-11-289] In the present study, α2M expression levels were upregulated in the DM1 group compared with HCs. In support of our data, Takada et al also showed that serum levels of α2M were clearly upregulated in many individuals with DM1 and type 2 diabetes mellitus (DM2).[@b23-dmso-11-289] Interestingly, upregulation of α2M has been suggested as a potential biomarker for diabetic retinopathy and nephropathy,[@b23-dmso-11-289]--[@b25-dmso-11-289] and studies have indicated that α2M can also act as a binding and carrier protein for cytokines, including IL-Iβ and IL-6, among others,[@b26-dmso-11-289] leading to the induction of several defense reactions, such as immune response, acute phase reaction, and hematopoiesis.[@b22-dmso-11-289] Therefore, acting as a carrier and binding protein could be the mechanism by which α2M performs its immune functions, acting in inflammatory processes, and could explain its enhanced expression in the serum of people with DM1.

Proteomic analysis has shown upregulated expression levels of IGHA2 in DM1 patients. IGHA2 is an immunoglobulin that is a membrane-bound or secreted glycoprotein produced by B lymphocytes.[@b27-dmso-11-289] This immunoglobulin has an important role in immune defense, especially at the mucosal surfaces.[@b28-dmso-11-289] In our study, the high levels of IGHA2 identified are in keeping with previous reports that have shown increased concentrations of circulating IgHA2 in DM1 and DM2 patients.[@b29-dmso-11-289]--[@b31-dmso-11-289] In DM1 patients, the increased expression in the serum of IGHA2 could be triggered in response to antigenic stimuli, forming continuous stimulation of antibody production.[@b29-dmso-11-289] Moreover, the literature shows that the relationship between diabetes and IGHA2 has been described as involving advanced glycation products. Some studies reported a significant increase in the glycation of IGHA2 in the plasma of patients with DM1 and with complications of diabetes, especially in retinopathy, nephropathy, and neuropathy.[@b32-dmso-11-289],[@b33-dmso-11-289] In addition, a cross-sectional study reported that increased levels of IgA tended to be associated with hyperglycemia.[@b34-dmso-11-289] In this context, it was suggested that high levels of IGHA2 result from an immune response to advanced glycosylation end products that increase and accumulate with persistent high blood glucose in patients with diabetes.[@b31-dmso-11-289]

ApoA-II expression levels were upregulated in the DM1 group compared with the HC group. APOA-II is the second most abundant apolipoprotein constituent of HDL, and the increased expression of APOA-II has been associated with several aspects of HDL, triglycerides, obesity, and insulin resistance.[@b35-dmso-11-289],[@b36-dmso-11-289] DM1 patients often show lipid disorders, such as abnormalities in the regulation of plasma lipid metabolism,[@b37-dmso-11-289] in different amounts of classes of lipoproteins, and in the transfer of lipids.[@b38-dmso-11-289] Lipoprotein abnormalities might contribute to the development of atherogenesis and diabetic nephropathy.[@b39-dmso-11-289],[@b40-dmso-11-289] In fact, Soedamah-Muthu et al reported that a lower APOA-I to APO-II ratio in patients with microalbuminuria or macroalbuminuria could contribute to an increased risk of cardiovascular disease.[@b41-dmso-11-289] Increased expression of APOA-II in transgenic mice showed enhanced HDL levels and increased size of HDL particles. Larger HDL observed is caused, in part, by the inhibition of the ability of hepatic lipase (HL) to hydrolyze phospholipids and triglycerides by APOA-II as well as an increased ratio of APOA-I to APOA-II. Therefore, interactions of APOA-II and APOA-I and HL influence the HDL structure and antiatherogenic properties.[@b42-dmso-11-289],[@b43-dmso-11-289] Furthermore, an excess of APOA-II in HDL may contribute to hypertriglyceridemia by inhibiting the lipolysis of triglyceride-rich lipoproteins and by modifying the lipoprotein lipase activity.[@b44-dmso-11-289] In diabetes, deficient function of insulin-dependent lipoprotein lipase may lead to hypertriglyceridemia as well as decreased HDL cholesterol levels due to increased lipid exchanges between triglyceride-rich lipoproteins and HDL.[@b37-dmso-11-289] Nevertheless, studies using various approaches have described APOA-II as both proatherogenic and antiatherogenic; however, the role of this protein in lipid metabolism and atherogenesis is not well understood. Nevertheless, evidence supports the hypothesis that APOA-II is antiatherogenic, and further studies are required.[@b45-dmso-11-289] Taken together, these data indicate that APOA-II plays an important role in regulating lipid and β-cell metabolism. Thus, in the current study, our observation supports previous reports that show an association between apolipoproteins and DM1.

β2 glycoprotein I, also known as apolipoprotein H (APOH), is involved in the inhibition of the intrinsic pathway of the activation of blood coagulation. There is evidence to support the association between APOH and lipid metabolism, inflammation, thrombosis, autoimmune disease, and atherosclerosis.[@b46-dmso-11-289],[@b47-dmso-11-289] Here, expression levels of APOH were upregulated in DM1 patients. The analysis of plasma levels of APOH from people with DM2 showed that patients with hypertriglyceridemia had significantly higher APOH values.[@b46-dmso-11-289] Others studies have shown an association between APOH and diabetic retinopathy and found increased levels of APOH in the vitreous fluid of DM1 patients with proliferative diabetic retinopathy.[@b48-dmso-11-289],[@b49-dmso-11-289] However, to our knowledge, no study has yet shown increased levels of APOH in the serum of DM1 patients. Interestingly, APOH binds apoptotic cells in vivo, and this might trigger or enhance complement activation, thus facilitating the recognition and clearance of apoptotic cells.[@b50-dmso-11-289] The role of APOH in the pathogenesis of diabetic retinopathy remains to be elucidated, but it could be related to complement activation or its potential role in the recognition of dying cells.[@b49-dmso-11-289] Although the relationship between cell apoptosis and autoimmunity remains to be fully established, there is evidence that T-cell-induced apoptosis is a mechanism in DM1.[@b51-dmso-11-289] Here, we show for the first time the upregulation of APOH in the serum of patients with DM1.

C4 was downregulated in the serum from patients with DM1. The complement system plays an important role in innate and acquired immunity, and evidence suggests that relevant target regulation of the complement system might be efficient in controlling autoimmune diseases.[@b52-dmso-11-289] Abnormalities in complement proteins in DM1 patients have been reported, and reduced levels of C4 were attributed to hypercatabolism or reduction in protein synthesis.[@b53-dmso-11-289] Moreover, decreased levels of C4 in children and adolescents with DM1 were related to impaired metabolic control.[@b54-dmso-11-289] High glucose interferes with the innate function of the complement system and impairs the ability of the host to combat infection.[@b55-dmso-11-289] Deficiencies in C4 are strongly associated with autoimmunity humoral and lead to impaired humoral responses.[@b52-dmso-11-289] Thus, the upregulation of C4 observed in this study is suggestive of loss of some functions of the complement system and thus increased risk of infectious processes and impaired metabolic control in DM1.

AMBP is a serum protein filtered by the glomerular membrane in the proximal tubule.[@b56-dmso-11-289],[@b57-dmso-11-289] Increased urinary excretion of this protein was observed in DM1 patients in the presence of microalbuminuria and normoalbuminuria.[@b57-dmso-11-289] In this sense, new research has indicated some biomarkers that precede albuminuria and have been detected in both DM1 and DM2 patients with early renal dysfunction.[@b58-dmso-11-289] AMBP has been proposed as a biomarker of tubular dysfunction in the early stages of diabetic nephropathy and in the late stages of chronic kidney disease.[@b59-dmso-11-289]--[@b62-dmso-11-289] Increased excretion urinary of AMBP has been frequently identified in patients with diabetes, compared with the control group.[@b57-dmso-11-289] Increased levels of AMBP suggest that serum AMBP may play a role in the regulation of inflammatory processes,[@b62-dmso-11-289] such as that occurs in diabetes. Interestingly, our study also showed that increased levels of AMBP occur in the serum proteome of DM1 patients, and to the best of our knowledge, this is the first study to observe this protein in serum from DM1 patients.

THRB is the protein precursor of thrombin, which plays a key role in thrombosis by converting fibrinogen to fibrin.[@b63-dmso-11-289]

Diabetes is associated with a number of changes in thrombotic and fibrinolytic coagulation factor level/activity, which collectively increase the risk of thrombus formation.[@b63-dmso-11-289] Thrombin generation is enhanced in both DM1 and DM2 individuals, secondary to low-grade activation of the coagulation system.[@b64-dmso-11-289] It has been suggested that elevated THRB levels can contribute both to thrombotic risk and to shortened clotting times in patients with diabetes.[@b65-dmso-11-289] In this sense, hyperglycemia has been associated with enhanced thrombin production, and controlling glucose levels results in reduced thrombin generation, suggesting that hyperglycemia is prothrombotic.[@b64-dmso-11-289] Conversely, hypoglycemia is also associated with enhanced clot formation.[@b63-dmso-11-289] Here, we identified that THRB was upregulated in the serum of DM1 patients, which is an important component in the pathway of coagulation. This is in accordance with previous studies showing that this protein is suggestive of poorly controlled diabetes.

PZP was shown to be downregulated in the serum of DM1 patients compared with HCs. PZP is one of the most abundant pregnancy glycoprotein-associated plasma proteins with described immune inhibitory activities and is remarkably homologous to α2M.[@b66-dmso-11-289],[@b67-dmso-11-289] Several studies have suggested that PZP has immunosuppressive properties in pregnancy, indicating a role for this protein in maintaining immune tolerance to the fetus and equilibrating the maternal immune response.[@b66-dmso-11-289],[@b68-dmso-11-289] In fact, serum levels increase during gestation (up to 1,000 mg/L).[@b69-dmso-11-289] Furthermore, high serum levels of PZP have been observed in relation to some diseases, including inflammatory conditions, such as rheumatoid arthritis and also in people who later developed Alzheimer's disease.[@b70-dmso-11-289],[@b71-dmso-11-289] In the current study, we observed downregulation of PZP expression in the DM1 group compared with HCs. This finding is very relevant because, to our knowledge, this is the first report of low levels of PZP in the serum of DM1 patients. The reduction of this protein in DM1 patients suggests that there could be a suppression mechanism of it, thereby avoiding inhibition of the activation of T lymphocytes against the pancreatic β-cells. It has been suggested that PZP contributes to immune regulation by noncovalently sequestering a variety of other ligands such tumor necrosis factor-α, IL-2, and IL-6.[@b72-dmso-11-289] In addition, Skornicka et al demonstrated that both native and activated PZP isoforms inhibited the activation of T-cell growth and IL-2 production.[@b66-dmso-11-289] DM1 is thought to involve chronic inflammation, leading to the release and increased activity of various immune system cells with a central role for T cells and macrophages.[@b73-dmso-11-289] Studies have shown that some inflammatory markers are enhanced in individuals with DM1 compared with those without.[@b74-dmso-11-289],[@b75-dmso-11-289] Taken together, our results suggest that PZP could be a target for a potential DM1 therapy.

Conclusion
==========

In conclusion, we used a proteomic approach with label-free MS^E^ analysis as a strategy to discover differential protein profiles between the serum of patients with DM1 and HCs.

We identified proteins that were expressed in differential levels in the serum of patients with DM1 compared with HCs. In addition, to our knowledge, we described the first evidence for changes in expression levels of PZP and APOH in the serum of DM1 patients.

Our results showed differential expression of proteins related to immune system, lipid metabolism, and coagulation pathways, which may be correlated to the development and progression of DM1. Accordingly, these findings need to be fully investigated and validated in future studies.

Supplementary material
======================

###### 

List of serum proteins between type 1 diabetes patients and healthy controls as identified by LC--MS^E^ analysis

  Accession number   Protein name                                                             Molecular weight   Matched peptides   Coverage (%)   Score
  ------------------ ------------------------------------------------------------------------ ------------------ ------------------ -------------- -----------
  P43652             Afamin                                                                   69,069             4/61               11.52          100.66
  P02763             Alpha-1-acid glycoprotein 1                                              23,512             9/17               53.73          11,680.58
  P19652             Alpha-1-acid glycoprotein 2                                              23,603             8/19               39.80          8,975.25
  P01011             Alpha-1-antichymotrypsin                                                 47,651             16/31              45.63          4,340.51
  P01009             Alpha-1-antitrypsin                                                      46,737             34/35              62.44          13,832.54
  P04217             Alpha-1B-glycoprotein                                                    54,254             8/26               51.31          6,138.02
  P08697             Alpha-2-antiplasmin                                                      54,566             7/34               25.46          694.29
  P02765             Alpha-2-HS glycoprotein                                                  39,325             4/18               50.68          2,842.23
  P01023             Alpha-2-macroglobulin                                                    163,291            66/95              69.54          11,454.35
  P01019             Angiotensinogen                                                          53,154             12/25              35.26          4,547.05
  Q9UJ72             Annexin A10                                                              37,278             4/35               10.19          134.28
  P02647             Apolipoprotein A I                                                       30,778             27/32              68.54          29,954.64
  P02652             Apolipoprotein A II                                                      11,175             6/11               72.00          9,656.85
  P06727             Apolipoprotein A IV                                                      45,399             12/42              54.55          2,142.37
  P02656             Apolipoprotein C III                                                     10,852             3/10               36.36          12,643.42
  P05090             Apolipoprotein D                                                         21,276             7/12               30.69          1,265.36
  P02649             Apolipoprotein E                                                         36,154             6/30               20.19          350.88
  P02749             Beta 2 glycoprotein 1                                                    38,298             14/22              62.03          4,930.08
  Q9Y5Z0             Beta secretase 2                                                         56,181             3/23               9.46           140.23
  P22792             Carboxy peptidase N subunit 2                                            60,557             5/30               13.03          334.61
  O43866             CD5 antigen like                                                         38,088             8/31               43.80          614.25
  Q7L2Z9             Centromere protein Q                                                     30,595             4/28               17.16          121.48
  O43303             Centriolar coiled coil protein of 110 kDa                                113,424            9/80               10.67          226.74
  P00450             Ceruloplasmin                                                            122,205            27/80              57.28          3,369.44
  P10909             Clusterin                                                                52,495             12/36              32.96          3,176.77
  P00748             Coagulation factor XII                                                   67,792             4/40               5.37           96.90
  P13671             Complement component C6                                                  104,787            10/65              9.31           159.79
  P01024             Complement C3                                                            187,149            61/136             51.41          8,628.71
  P0C0L4             Complement C4 A                                                          192,785            52/118             54.59          5,352.24
  P0C0L5             Complement C4 B                                                          192,752            44/117             48.57          5,333.65
  P00751             Complement factor B                                                      85,533             23/64              38.09          1,924.60
  P08603             Complement factor H                                                      139,097            33/96              40.70          1,155.49
  P05156             Complement factor I                                                      65,751             2/42               5.49           117.71
  P08185             Corticosteroid binding globulin                                          45,141             6/23               27.90          371.10
  P04003             C4b binding protein alpha chain                                          67,033             13/45              30.82          1,198.61
  A6NLW8             Double homeobox protein A                                                23,817             1/21               13.24          142.05
  O43543             DNA repair protein XRCC2                                                 31,957             2/19               10.36          182.94
  Q9NPG1             Frizzled 3                                                               76,263             2/54               6.16           148.64
  P06396             Gelsolin                                                                 85,968             17/51              32.86          661.02
  Q969I3             Glycine N-acyltransferase like protein1                                  35,101             3/17               11.26          149.87
  Q13588             GRB2 related adapter protein                                             25,337             2/20               26.27          389.12
  O96020             G1 S specific cyclin E2                                                  46,757             4/29               11.88          105.55
  P00738             Haptoglobin                                                              45,205             27/28              70.94          17,966.31
  P00739             Haptoglobin related protein                                              3,903              20/25              46.26          7,405.70
  P69905             Hemoglobin subunit alpha                                                 15,256             6/9                76.76          3,268.27
  P68871             Hemoglobin subunit beta                                                  15,998             7/13               57.82          4,909.04
  P02042             Hemoglobin subunit delta                                                 16,056             5/13               29.25          4,275.18
  P02100             Hemoglobin subunit epsilon                                               16,203             2/14               21.77          4,275.18
  P69891             Hemoglobin subunit gamma 1                                               16,140             5/13               40.82          4,306.96
  P69892             Hemoglobin subunit gamma 2                                               16,126             4/13               38.10          4,295.91
  P02790             Hemopexin                                                                51,677             21/34              50.87          16,740.46
  P05546             Heparin cofactor 2                                                       57,071             7/36               11.62          295.97
  P04196             Histidine rich glycoprotein                                              59,578             12/33              24.95          1,886.61
  P17482             Homeobox protein Hox B9                                                  28,059             1/23               15.20          155.80
  P01876             Ig alpha-1-chain C region                                                37,655             20/23              67.42          19,361.04
  P01877             Ig alpha-2-chain C region                                                36,526             15/22              69.41          11,700.44
  P01857             Ig gamma 1 chain C region                                                36,106             9/21               37.58          1,570.00
  P01859             Ig gamma 2 chain C region                                                35,901             4/20               17.18          300.21
  P01860             Ig gamma 3 chain C region                                                41,287             4/24               12.20          702.83
  P01861             Ig gamma 4 chain C region                                                35,941             7/20               33.94          1,236.51
  P01766             Ig heavy chain VIII region BRO                                           13,227             4/6                40.83          4,324.36
  P01767             Ig heavy chain VIII region BUT                                           11,906             1/8                9.57           976.53
  P01774             Ig heavy chain VIII region POM                                           12,710             1/8                15.97          2,043.78
  P01777             Ig heavy chain VIII region TEI                                           12,559             2/6                36.13          4,324.36
  P01765             Ig heavy chain VIII region TIL                                           11,612             2/6                33.04          2,043.78
  P01779             Ig heavy chain VIII region TUR                                           12,188             1/7                16.38          2,043.78
  P01776             Ig heavy chain VIII region WAS                                           12,847             2/7                29.91          2,043.78
  P01763             Ig heavy chain VIII region WEA                                           12,142             1/6                9.65           976.53
  P01764             Ig heavy chain VIII region 23                                            12,582             2/8                18.80          965.64
  P01871             Ig mu chain C region                                                     49,307             25/38              63.94          8,892.79
  P04220             Ig mu heavy chain disease protein                                        43,057             22/35              52.94          12,444.26
  P01834             Ig kappa chain C region                                                  11,609             7/7                80.19          26,627.65
  P01614             Ig kappa chain VII region Cum                                            12,676             1/7                11.30          787.52
  P06309             Ig kappa chain VII region GM607 Fragment                                 12,664             2/5                31.62          567.77
  P06310             Ig kappa chain VII region RPMI 6410                                      14,707             2/7                29.32          622.24
  P06617             Ig kappa chain V II region TEW                                           2,059              2/5                32.74          571.31
  P04206             Ig kappa chain VIII region GOL                                           11,830             2/8                31.19          1,520.77
  P18135             Ig kappa chain VIII region HAH                                           14,073             2/8                26.36          1,260.29
  P18136             Ig kappa chain VIII region HIC                                           14,089             2/7                26.36          1,260.29
  P01621             Ig kappa chain VIII region NG9 Fragment                                  10,729             2/6                56.00          590.59
  P01620             Ig kappa chain VIII region SIE                                           11,775             4/6                66.06          1,600.43
  P01623             Ig kappa chain VIII region WOL                                           11,746             3/7                51.38          1,622.15
  P01622             Ig kappa chain VIII region TI                                            11,778             3/6                51.38          1,520.77
  P04206             Ig kappa chain VIII region GOL                                           11,830             2/8                31.19          1,520.77
  P0CG04             Ig lambda 1 chain C region                                               11,348             5/7                65.09          38,924.68
  P0CG05             Ig lambda 2 chain C region                                               11,294             6/7                77.36          39,000.63
  P0CG06             Ig lambda 3 chain C region                                               11,238             5/7                76.42          39,000.63
  P0CF74             Ig lambda 6 chain C region                                               11,277             5/6                77.36          24,818.13
  A0M8Q6             Ig lambda 7 chain C region                                               11,303             4/7                46.23          24,610.28
  P01591             Immunoglobulin J chain                                                   18,099             4/11               34.59          1,818.20
  P35858             Insulin like growth factor binding protein complex acid labile subunit   66,035             6/35               12.56          119.96
  B9A064             Immunoglobulin lambda like polypeptide 5                                 23,063             6/12               42.99          38,934.43
  P19827             Inter-alpha trypsin inhibitor heavy chain H1                             101,389            19/56              31.61          1,735.56
  P19823             Inter-alpha trypsin inhibitor heavy chain H2                             106,464            21/70              32.77          1,415.98
  Q14624             Inter-alpha trypsin inhibitor heavy chain H4                             103,358            22/64              40.00          1,410.90
  Q5T749             Keratinocyte proline rich protein                                        64,136             1/29               9.33           133.79
  P01042             Kininogen 1                                                              71,958             13/61              39.13          1,470.83
  P02750             Leucine-rich alpha-2-glycoprotein                                        38,178             6/24               26.80          925.55
  O15165             Low-density lipoprotein receptor class A domain containing protein       33,900             2/19               12.42          142.67
  Q96PD5             N acetylmuramoyl L alanine amidase                                       62,217             7/36               23.61          381.10
  Q13516             Oligodendrocytetranscriptionfactor2                                      32,385             2/16               20.74          356.38
  P05155             Plasma protease C1 inhibitor                                             55,154             7/29               21.60          1,325.77
  P00747             Plasminogen                                                              90,569             15/63              26.91          318.40
  P02775             Platelet basic protein                                                   13,894             3/9                46.09          801.19
  P20742             Pregnancy zone protein                                                   163,863            16/87              21.52          1,774.43
  P02760             Protein AMBP                                                             38,999             10/26              37.78          2,146.99
  Q9UJC3             Protein Hook homolog 1                                                   84,648             8/69               13.87          65.59
  P00734             Prothrombin                                                              70,037             14/47              35.69          1,449.93
  Q9H5L9             Putative uncharacterized protein C5orf66                                 1,557              1/8                24.83          115.20
  O00472             RNA polymerase II elongation factor ELL2                                 7,232              5/74               9.69           163.86
  Q9NP77             RNA polymerase II subunit A C terminal domain phosphatase SSU72          22,575             7/17               43.30          179.28
  Q96HS1             Serine threonine protein phosphatase PGAM5 mitochondrial                 32,005             3/23               11.76          229.10
  P02787             Serotransferrin                                                          77,064             42/76              72.78          42,299.91
  P02768             Serum albumin                                                            69,367             54/55              38.92          4,317.47
  P27169             Serum paraoxonase arylesterase 1                                         39,731             7/18               50.99          2,611.12
  P04278             Sex hormone binding globulin                                             43,779             4/29               25.62          210.35
  O00337             Sodium nucleoside cotransporter                                          71,584             3/35               3.39           102.95
  Q13596             Sortingnexin1                                                            5,907              3/40               11.88          178.19
  O60235             Transmembrane protease serine 11D                                        46,264             2/20               11.48          122.25
  P02766             Transthyretin                                                            15,887             4/9                50.34          302.37
  Q9NZQ9             Tropomodulin 4                                                           39,336             3/32               26.09          192.01
  Q5SQH8             Uncharacterized protein C6orf 136                                        35,794             2/16               29.84          122.10
  Q8N865             Uncharacterized protein C7orf 31                                         68,465             4/49               12.03          47.34
  Q6UXV3             Uncharacterized protein UNQ6126                                          16,883             1/8                36.31          161.41
  P02774             Vitamin D binding protein                                                52,964             24/45              67.93          3,508.70
  P04004             Vitronectin                                                              54,306             10/28              38.49          2,808.10
  P25311             Zinc alpha-2-glycoprotein                                                34,259             9/27               48.66          2,246.30
  P21506             Zinc finger protein 10                                                   66,455             4/45               9.60           220.02
  Q86UK7             Zinc finger protein 598                                                  98,637             6/71               10.18          161.99

**Abbreviations:** AMBP, alpha-1-microglobulin; LC--MS^E^, liquid chromatography--data-independent label-free mass spectrometry.
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![Diagram of the study design used for research of proteomic biomarker in the serum of individuals.\
**Abbreviations:** LC--MSE, liquid chromatography----data-independent label-free mass spectrometry; IgG, immunoglobulin G.](dmso-11-289Fig1){#f1-dmso-11-289}
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###### 

Demographic, anthropometric, and clinical characteristics of participants in study

  Parameters                  Patients with DM1   HC               *p*-value
  --------------------------- ------------------- ---------------- ----------------------------------------------------
  Subjects (n)                30                  30               --
  Age (years)                 35.03 (8.60)        31.50 (10.67)    0.163[a](#tfn2-dmso-11-289){ref-type="table-fn"}
  BMI (kg/m^2^)               24.76 (3.10)        24.74 (4.03)     0.982[a](#tfn2-dmso-11-289){ref-type="table-fn"}
  DM1 duration (years)        15.63 (10.47)       --               --
  HbA1c (%)                   7.5 (1.2)           --               --
  Blood glucose (mg/dL)       145.44 (56.96)      89.93 (6.02)     \<0.001[b](#tfn3-dmso-11-289){ref-type="table-fn"}
  Peptide C (ng/mL)           0.14 (0.17)         3.92 (0.56)      \<0.001[b](#tfn3-dmso-11-289){ref-type="table-fn"}
  Total cholesterol (mg/dL)   179.68 (39.12)      192.56 (36.59)   0.193[a](#tfn2-dmso-11-289){ref-type="table-fn"}
  LDL (mg/dL)                 87.88 (36.34)       88.90 (31.73)    0.907[a](#tfn2-dmso-11-289){ref-type="table-fn"}
  HDL (mg/dL)                 73.70 (25.65)       76.83 (22.86)    0.619[a](#tfn2-dmso-11-289){ref-type="table-fn"}
  TG (mg/dL)                  141.80 (34.80)      95.11 (26.01)    \<0.001[b](#tfn3-dmso-11-289){ref-type="table-fn"}
  Total proteins (mg/dL)      7.24 (1.01)         7.24 (1.26)      0.564[b](#tfn3-dmso-11-289){ref-type="table-fn"}
  Creatinine (mg/dL)          0.91 (0.21)         0.92 (0.23)      0.863[a](#tfn2-dmso-11-289){ref-type="table-fn"}
  Urea (mg/dL)                33.03 (11.47)       25.97 (7.72)     0.007[a](#tfn2-dmso-11-289){ref-type="table-fn"}
  Gender                                                           
   Male n (%)                 12 (63.16)          7 (36.84)        0.165[a](#tfn2-dmso-11-289){ref-type="table-fn"}
   Female n (%)               18 (43.90)          23 (56.10)       
  Smoking n (%)                                                    
   Yes                        2 (66.67)           1 (33.33)        1\. 000[b](#tfn3-dmso-11-289){ref-type="table-fn"}
   No                         28 (49.12)          29 (50.88)       
  Drinking n (%)                                                   
   Yes                        0 (0.00)            1 (100.00)       1\. 000[b](#tfn3-dmso-11-289){ref-type="table-fn"}
   No                         30 (50.85)          29 (49.15)       

**Notes:** Values are expressed as mean (SD) and number (percentage).

Student's *t*-test;

Mann--Whitney test; *p*-values \<0.05 are considered significant.

**Abbreviations:** BMI, body mass index; DM1, type 1 diabetes mellitus; HbA1c, glycated hemoglobin; HC, healthy controls; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides.

###### 

Characterization of differentially expressed proteins in serum of DM1 patients compared with HCs as identified by LC--MS^E^

  Accession number   Protein name                Molecular weight   Matched peptides   Coverage (%)   Score       DM1/HC[a](#tfn5-dmso-11-289){ref-type="table-fn"}   Expression   Function
  ------------------ --------------------------- ------------------ ------------------ -------------- ----------- --------------------------------------------------- ------------ --------------------------------------------------------------------------------------
  P01023             Alpha-2-macroglobulin       163,291            66/95              69.54          11,454.35   1.64                                                Up           Cellular process/regulation
  P02760             Protein AMBP                38,999             10/26              37.78          2,146.99    1.58                                                Up           Cellular process/process metabolic/immune system
  P02652             Apolipoprotein A II         11,175             6/11               72.00          9,656.85    1.84                                                Up           Cellular process/developmental process/response to stimulus/metabolic process
  P02749             Beta-2-glycoprotein 1       38,298             14/22              62.03          4,930.08    1.72                                                Up           Cellular process/localization/metabolic process/regulation
  P01877             Ig alpha-2 chain C region   36,526             15/22              37.58          11,700.44   2.14                                                Up           Cellular process/regulation/immune system
  P00734             Prothrombin                 70,037             14/47              35.69          1,449.93    1.60                                                Up           Cellular process/developmental and metabolic process/regulation/response to stimulus
  P0C0L4             Complement C4 A             192,785            52/118             54.59          5,352.24    0.54                                                Down         Immune system/regulation/response to stimulus
  P20742             Pregnancy zone protein      163,863            16/87              21.52          1,774.43    0.41                                                Down         Interaction with cells and organisms

**Notes:**

Average differences of replicate samples run to type 1 diabetes patients compared with healthy control. Proteins are shown as 1.5-fold differences either upregulated or downregulated (*p*\<0.05). Functions were assigned according to the String databases and literature search.

**Abbreviations:** AMBP, alpha-1-microglobulin; DM1, type 1 diabetes mellitus; HC, healthy control; LC--MS^E^, liquid chromatography--data-independent label-free mass spectrometry.
